상세 보기
Final overall survival (OS) and safety analysis of the Phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC)
- Buchmeier, Eva Lotte;
- Mok, Tony;
- Camidge, D. Ross;
- Dziadziuszko, Rafal;
- Gadgeel, Shirish;
- ... Ahn, Jin Seok;
- 외 15명
Citations
WEB OF SCIENCE
0- 제목
- Final overall survival (OS) and safety analysis of the Phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC)
- 저자
- Buchmeier, Eva Lotte; Mok, Tony; Camidge, D. Ross; Dziadziuszko, Rafal; Gadgeel, Shirish; Shaw, Alice T.; Kim, Dong-Wan; Perol, Maurice; Rosell, Rafael; Cheema, Parneet; Lim, Darren; Lin, Jessica J.; Pavlakis, Nick; Ahn, Jin Seok; Zhang, Li; Henschel, Volkmar; Higgerson, Agata; McNally, Virginia; Lohmann, Tania Ochi; Smoljanovic, Vlatka; Peters, Solange
- 발행일
- 2026-02
- 유형
- Meeting Abstract
- 권
- 49
- 페이지
- 288 ~ 289